Tiziana Life Sciences Market Sentiment - Benzinga

Tiziana Life Sciences Ltd

TLSANASDAQ

Trade with Public

Trade with Public

$0.9900

-0.02-1.98%

At close: Aug 11, 5:00 PM EST

$1.00

-0.01-0.99%

Pre-Market: 6:12 AM EST

Overview News Earnings Forecast Events FinancialsSentimentOwnership Compare Options Stock Report

Tiziana Life Sciences Market Sentiment

Market sentiment signals for Tiziana Life Sciences (TLSA): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus— N/A

Short Interest▼ 2.0% short float

Options Flow— N/A

Insider Activity▲ Net Buyer (30d)

Analyst Consensus

—

Options Flow (P/C)

—

Avg Consensus PT

—

Highest Price Target

—

Lowest Price Target

—

Short Interest

2.0%

Rising — Bearish

Insider Activity (30d)

Net Buyer

Short Interest — % of Float

Insider & Market Activity News

PRO
Tiziana Life Sciences Announces CEO Ivor Elrifi Purchased 667,000 Common Shares At $1.00 Per Share, Raising Total Holding To 4,472,261 Shares

Benzinga Newsdesk

PRO
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Buys 42,357 Shares At $0.99 Per Share, Bringing Total Holding To 44,814,587 Shares, 34.93% Of Issued Share Capital

Benzinga Newsdesk

PRO
Tiziana Life Sciences CEO Ivor Elrifi Buys 163,400 Shares In Open Market, Increases Total Holdings To 357,848 Shares

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,

Benzinga Newsdesk

PRO
Tiziana Life Sciences Announces CEO Ivor Elrifi Purchased 193,848 Shares At $1.65/Share

Benzinga Newsdesk

Tiziana Life Sciences Announces Purchase Of 7,500 Common Shares By Acting CEO At $0.79/Share

Bill Haddad

Tiziana Life Sciences Announces Purchase Of 45K Common Shares At A Price Of $0.66/Share By Chairman And Acting CEO

Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been

Happy Mohamed